News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synthon Pharmaceuticals Appoints Paul Roos as Chief Financial Officer


5/7/2012 10:20:40 AM

Nijmegen, the Netherlands, 7 May 2012 – Synthon today announced that it has appointed Paul Roos as chief financial officer (CFO). Paul will also serve as a member of Synthon’s executive board.

Paul comes to Synthon from Kempen & Co, a Dutch merchant bank, where he worked for ten years, most recently as Executive Director of Corporate Finance. In this high-profile position, he was accountable for building and maintaining relationships, originating new mandates and executing transactions with a focus on European Life Sciences & Healthcare as well as European Cleantech companies. In this capacity, he concluded over 35 transactions across a broad range of industries.

Paul simultaneously obtained a master of econometrics (cum laude) and a master of business economics (cum laude) of the University of Amsterdam and followed exchange programs at New York University and UPF Barcelona.

Synthon CEO Rudy Mareel commented: “I am excited to have Paul on-board as we enter a key phase in Synthon’s development. We are poised for significant expansion in our generics business with a strong and rejuvenated pipeline, while our biopharmaceuticals organization continues to mature with emerging partnerships and a sharper R&D focus. Paul’s deep knowledge of the healthcare and life sciences industry as well as his strong financial background are well-suited to our needs over the coming years and I am confident that he can add tremendous value to our company.”

About Synthon

Synthon, with headquarters in Nijmegen, the Netherlands is an international fast-growing pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune disease, multiple sclerosis and oncology. Our products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon employs about 1,400 staff at 11 sites worldwide, and in 2011 it recorded a turnover of EUR 260 million. For more information, go to www.synthon.com.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES